
Sanofi has announced new Phase III data for its IGlarLixi combination drug for the treatment of diabetes, showing it could …

There was unfortunate news for Sanofi and Zealand Pharma as the FDA announced that it required additional information, constituting a …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

